Identification and validation of LINC01322 as a potential prognostic biomarker and oncogene promoting tumor progression in lung adenocarcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.We discovered LINC01322, a novel long noncoding RNA, promotes lung adenocarcinoma by activating the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. This finding suggests LINC01322 as a potential therapeutic target for lung cancer.
Area Of Science
- Molecular Biology
- Oncology
- Genetics
Background
- Lung adenocarcinoma is a major cause of cancer mortality.
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.
- The specific functions of many lncRNAs in lung adenocarcinoma remain unclear.
Purpose Of The Study
- To identify and characterize novel lncRNAs involved in lung adenocarcinoma.
- To elucidate the molecular mechanisms by which LINC01322 influences lung adenocarcinoma progression.
- To evaluate the therapeutic potential of targeting LINC01322.
Main Methods
- Identification of LINC01322 through molecular screening.
- Cellular localization assays (cytoplasmic and nuclear RNA purification).
- Gene set enrichment analysis (GSEA) to identify associated pathways.
- In vitro experiments: LINC01322 knockdown and overexpression in lung adenocarcinoma cells.
- In vivo xenograft models to assess tumor growth.
- Pharmacological inhibition of the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway.
Main Results
- LINC01322 was identified as a novel lncRNA upregulated in lung adenocarcinoma.
- LINC01322 is localized in both the cytoplasm and nucleus.
- LINC01322 promotes lung adenocarcinoma cell proliferation and migration.
- LINC01322 activates the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway.
- Knockdown of LINC01322 suppressed tumor growth and JAK2/STAT3 activation.
- Overexpression of LINC01322 enhanced tumor growth and JAK2/STAT3 activation.
- Inhibition of JAK2/STAT3 partially reversed LINC01322-induced proliferation and migration.
Conclusions
- LINC01322 functions as an oncogene in lung adenocarcinoma progression.
- LINC01322 promotes tumor growth and metastasis by activating the JAK2/STAT3 pathway.
- LINC01322 represents a promising therapeutic target for lung adenocarcinoma treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
